Scientific Reports · 2018 · 17 citations · 26 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyHematologic Malignancy TherapyLigand-based DesignOncology PharmacologyTargeted TherapyTyrosine Kinase InhibitorsAcute Myeloid Leukemia TherapyCell-based AssaysFlt3 InhibitionFlt3 InhibitorsPyrimidine AnalogsPyrimidine AnaloguesRational DesignType Ii Kinase Inhibitors
Abstract FMS-like Tyrosine Kinase 3 (FLT3) is a clinically validated target for acute myeloid leukemia (AML). Inhibitors targeting FLT3 have been evaluated in clinical studies and have exhibited potential to treat FLT3-driven AML. A frequent, clinical limitation is FLT3 selectivity, as concomitant inhibition of FLT3 and c-KIT is thought to cause dose-limiting myelosuppression. Through a rational design approach, novel FLT3 inhibitors were synthesized employing a pyridine/pyrimidine warhead. The most potent compound identified from the studies is compound 13a , which exhibited an IC 50 value of 13.9 ± 6.5 nM against the FLT3 kinase with high selectivity over c-KIT. Mechanism of action studies suggested that 13a is a Type-II kinase inhibitor, which was also supported through computer aided drug discovery (CADD) efforts. Cell-based assays identified that 13a was potent on a variety of FLT3-driven cell lines with clinical relevance. We report herein the discovery and therapeutic evaluation of 4,6-diamino pyrimidine-based Type-II FLT3 inhibitors, which can serve as a FLT3-selective scaffold for further clinical development.
26
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 745 citations
Medicine, Genetics, Hematology +13
Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2010 · 502 citations · Full text